Effect of weekly vitamin D supplementation on the severity of atopic dermatitis and type 2 immunity biomarkers in children: A randomized controlled trial

Arturo Borzutzky,Carolina Iturriaga,Guillermo Pérez‐Mateluna,Francisca Cristi,Lorena Cifuentes,Sergio Silva‐Valenzuela,Cristián Vera‐Kellet,Carolina Cabalín,Rodrigo Hoyos‐Bachiloglu,Cristian Navarrete‐Dechent,María Laura Cossio,Catalina Le Roy,Carlos A. Camargo,Catalina Le Roy
DOI: https://doi.org/10.1111/jdv.19959
2024-03-16
Journal of the European Academy of Dermatology and Venereology
Abstract:Background Vitamin D (VD) deficiency is common among patients with atopic dermatitis (AD) and often associated with severity. However, randomized trials of VD supplementation in AD have had equivocal results, and there is little information regarding the effect of VD supplementation on type 2 immunity in AD patients. Objectives To investigate the efficacy of VD supplementation to decrease severity of AD and to alter type 2 immunity biomarkers. Methods We performed a randomized, double‐blind, placebo‐controlled trial. We randomly assigned 101 children with AD to weekly oral vitamin D3 (VD3) or placebo for 6 weeks. The primary outcome was the change in the Severity Scoring of AD (SCORAD). Results Mean age of subjects was 6.3 ± 4.0 years, and baseline SCORAD was 32 ± 29. At baseline, 57% of children were VD deficient, with no difference between groups. Change in 25(OH)D was significantly greater with VD3 than placebo (+43.4 ± 34.5 nmol/L vs. +2.3 ± 21.2 nmol/L, p
dermatology
What problem does this paper attempt to address?